Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
about
Emerging treatment options for ovarian cancer: focus on rucaparib.Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.PARP inhibitors: Clinical utility and possibilities of overcoming resistance.A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.PARP inhibitors for homologous recombination-deficient prostate cancer.A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.Major clinical research advances in gynecologic cancer in 2017.Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways.Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trialsThe Chemoprevention of Ovarian Cancer: the Need and the OptionsLow-grade Serous Ovarian CarcinomaOptimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapyHomologous recombination deficiency in ovarian cancer: a review of its epidemiology and managementTargeted treatment of advanced ovarian cancer: spotlight on rucaparibMethylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
P2860
Q47107471-9310E532-60BA-4E62-86E6-40C7959F6575Q48124146-0372FC21-15E4-4DD1-A81E-6807F62D65E3Q48164214-4A609176-68E8-4977-AD20-F67D13423E76Q49723005-63875845-C8BA-412B-B2E2-46362F314581Q50076626-02330D8E-4E83-43CE-9098-E6524C7A6C24Q52430620-B9A01644-1B64-4696-90E0-95869BEACD38Q52623144-3C6F568D-3829-46A4-8A87-6DBBB659A28BQ52807922-DA9C5CD1-64E9-4DE4-A00E-EEE6ADAFDF60Q54952356-8F505F54-1697-4B40-A094-AC1742D12B11Q55041688-83366F17-03A6-49F8-AD95-B1E59611EA03Q55172706-9554BBFC-F55E-4B90-9F63-6D59C43209EBQ55211683-C5408439-375B-425B-854D-9758CFC60792Q55341383-1EED3337-F474-49C0-B3E2-97D75F294F39Q55416207-6CBF97E4-4116-4CE1-9D8E-D3E2C4B8878DQ55710290-3DC9F29B-BD44-416F-8A68-A1EC5F2A1F6CQ57074340-3DEC7DDC-DC4E-400E-AB42-74BD97807B15Q58579152-8C1FA5AE-E836-47A9-87B3-25C1C8577F06Q58592773-95506181-866D-4BBD-B6C6-A5EFD528C827Q58719363-A26BCE06-8E2F-481F-8B0F-D56A754BA58DQ58801181-62C1801C-6B23-41BA-BF4C-74FB4663A2F4Q59125756-5BF5D0D3-668A-40DF-B980-C1E292B9A46EQ59126243-F12EB52E-6979-4857-A5B5-7413E67D44EB
P2860
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Rucaparib maintenance treatmen ...... ebo-controlled, phase 3 trial.
@en
Rucaparib maintenance treatmen ...... ebo-controlled, phase 3 trial.
@nl
type
label
Rucaparib maintenance treatmen ...... ebo-controlled, phase 3 trial.
@en
Rucaparib maintenance treatmen ...... ebo-controlled, phase 3 trial.
@nl
prefLabel
Rucaparib maintenance treatmen ...... ebo-controlled, phase 3 trial.
@en
Rucaparib maintenance treatmen ...... ebo-controlled, phase 3 trial.
@nl
P2093
P2860
P50
P1433
P1476
Rucaparib maintenance treatmen ...... ebo-controlled, phase 3 trial.
@en
P2093
ARIEL3 investigators
Amit M Oza
Ana Oaknin
Andrew Clamp
Andrew Dean
Anne Floquet
Carol Aghajanian
Caroline Grace
Clare L Scott
David M O'Malley
P2860
P304
P356
10.1016/S0140-6736(17)32440-6
P407
P577
2017-09-12T00:00:00Z